|
Name |
N-(2-hydroxy-2-phenylethyl)acetamide
|
| Molecular Formula | C10H13NO2 | |
| IUPAC Name* |
N-(2-hydroxy-2-phenylethyl)acetamide
|
|
| SMILES |
CC(=O)NCC(C1=CC=CC=C1)O
|
|
| InChI |
InChI=1S/C10H13NO2/c1-8(12)11-7-10(13)9-5-3-2-4-6-9/h2-6,10,13H,7H2,1H3,(H,11,12)
|
|
| InChIKey |
KJCJYQYRPOJUKJ-UHFFFAOYSA-N
|
|
| Synonyms |
N-(2-hydroxy-2-phenylethyl)acetamide; 3306-05-6; N-(2-hydroxy-2-phenyl-ethyl)-acetamide; NSC114228; SCHEMBL885090; DTXSID90297124; AKOS008977316; alpha-(Acetylaminomethyl)benzyl alcohol; HY-W164451; NSC-114228; DS-011544; CS-0221825; EN300-100177; N-(2-HYDROXY-2-PHENYL-ETHYL)ACETAMIDE; Z255306774
|
|
| CAS | 3306-05-6 | |
| PubChem CID | 270963 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 179.22 | ALogp: | 0.4 |
| HBD: | 2 | HBA: | 2 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 49.3 | Aromatic Rings: | 1 |
| Heavy Atoms: | 13 | QED Weighted: | 0.734 |
| Caco-2 Permeability: | -4.605 | MDCK Permeability: | 0.00002670 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.102 |
| Human Intestinal Absorption (HIA): | 0.067 | 20% Bioavailability (F20%): | 0.065 |
| 30% Bioavailability (F30%): | 0.806 |
| Blood-Brain-Barrier Penetration (BBB): | 0.843 | Plasma Protein Binding (PPB): | 11.56% |
| Volume Distribution (VD): | 0.911 | Fu: | 76.22% |
| CYP1A2-inhibitor: | 0.073 | CYP1A2-substrate: | 0.095 |
| CYP2C19-inhibitor: | 0.06 | CYP2C19-substrate: | 0.812 |
| CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.101 |
| CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.337 |
| CYP3A4-inhibitor: | 0.009 | CYP3A4-substrate: | 0.196 |
| Clearance (CL): | 3.69 | Half-life (T1/2): | 0.718 |
| hERG Blockers: | 0.035 | Human Hepatotoxicity (H-HT): | 0.227 |
| Drug-inuced Liver Injury (DILI): | 0.031 | AMES Toxicity: | 0.071 |
| Rat Oral Acute Toxicity: | 0.015 | Maximum Recommended Daily Dose: | 0.092 |
| Skin Sensitization: | 0.147 | Carcinogencity: | 0.022 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.047 |
| Respiratory Toxicity: | 0.023 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000173 | ![]() |
0.561 | D00HHS | ![]() |
0.468 | ||
| ENC000693 | ![]() |
0.522 | D0LG8E | ![]() |
0.468 | ||
| ENC001819 | ![]() |
0.500 | D0R1CR | ![]() |
0.408 | ||
| ENC001934 | ![]() |
0.467 | D05OFX | ![]() |
0.387 | ||
| ENC001960 | ![]() |
0.467 | D0X9RY | ![]() |
0.386 | ||
| ENC000218 | ![]() |
0.455 | D0O6IU | ![]() |
0.380 | ||
| ENC000717 | ![]() |
0.453 | D00DZN | ![]() |
0.377 | ||
| ENC000191 | ![]() |
0.452 | D05OIS | ![]() |
0.372 | ||
| ENC000192 | ![]() |
0.452 | D0P6UB | ![]() |
0.367 | ||
| ENC000326 | ![]() |
0.448 | D01ZJK | ![]() |
0.367 | ||